Fate Therapeutics Inc. | Ownership
Companies that own Fate Therapeutics Inc.
Redmile Group LLC
6,655,962
12.46%
0
2.66%
07/31/2018
Fidelity Management & Research Co.
6,625,806
12.4%
-1,290,002
0.01%
06/30/2018
Franklin Advisers, Inc.
5,530,749
10.35%
-318,030
0.05%
06/30/2018
BlackRock Fund Advisors
3,018,321
5.65%
352,784
0%
06/30/2018
Casdin Capital LLC
2,600,000
4.87%
0
4.63%
06/30/2018
The Vanguard Group, Inc.
2,076,089
3.89%
313,021
0%
06/30/2018
SSgA Funds Management, Inc.
1,993,912
3.73%
1,206,749
0%
06/30/2018
Invus Public Equities Advisors LLC
1,700,000
3.18%
850,000
0.74%
06/30/2018
Westfield Capital Management Co. LP
805,460
1.51%
805,460
0.07%
06/30/2018
T. Rowe Price Associates, Inc.
789,096
1.48%
-173,677
0%
06/30/2018
| Address |
3535 General Atomics Court
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.fatetherapeutics.com |
| Updated |
07/08/2019 |
| Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. |
